Collection
covid-19
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trialAims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects in patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19. Main methods: From February 4 to February 28, 2020, 62 patients suffering from COVID-19 were diagnosed and admitted to Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial, 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ. Key findings: For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group and the HCQ group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group. Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 32) compared with the control group (54.8%, 17 of 32). Notably, all 4 patients progressed to severe illness that occurred in the control group. However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Significance: Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR2000029559 ### Funding Statement This study was supported by the Epidemiological Study of COVID-19 Pneumonia to Science and Technology Department of Hubei Province (2020FCA005). ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The dataset supporting the conclusions of this article is included within the article.
3Bill Gates: If I were president, this is what I would do now to fight coronavirusMicrosoft co-founder and billionaire philanthropist Bill Gates says if he were president of the United States, he would prioritize keeping everyone isolated to "flatten the curve." The billionaire says he would be clear that it will not be an easy time.
13There aren't enough ventilators for coronavirus, so a London, Ont., man giving his design awayRetired respiratory therapist John Strupat said he decided to make his design open source after he failed to get any kind of serious consideration to make the life-saving device for Canadian or U.S. governments.
4Stability and inactivation of SARS coronavirusThe SARS-coronavirus (SARS-CoV) is a newly emerged, highly pathogenic agent that caused over 8,000 human infections with nearly 800 deaths between November 2002 and September 2003. While direct person-to-person transmission via respiratory droplets accounted ...
5COVID-19 Science Update for March 27th: Super-Spreaders and the Need for New Prediction ModelsThis article constitutes the March 27th, 2020 entry in the daily Quillette series COVID-19 UPDATES. Please report needed corrections or suggestions to jon@quillette.com. According to statistics compiled by Our World in Data (OWD), the number of newly reported COVID-19 deaths increased yesterday. There were 2,681 new confirmed COVID-19 fatalities globally, compared to 2,423 reported on yesterday. This was largely due to increased death tallies in France (365 new deaths, up from 231 the day before), Italy (660, down from 685 reported on Thursday and 743 reported on Wednesday), Spain (655, down from 738) and the United States (246, virtually unchanged from Thursday’s report of 249, with the New York City area remaining the pandemic’s American epicenter). On Wednesday, I mentioned that just four countries—France, Italy, Spain, and the United States—represented 78 percent of that day’s newly reported global COVID-19 deaths. Yesterday, it was 79 percent. Today, it is 72 percent. In fact, this figure has remained above 65 percent for 17 of the last 18 days. In these four countries, the annualized per-capita death …
6Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes - Mar 27, 2020Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings- Abbott will be making ID NOW...
7